Spark Therapeutics (NASDAQ:ONCE) traded higher in the last at $53.58, gaining 0.03 points or 0.06%. From the data available, it can be said that the stock did not make an impact in the money flow department with the net figure coming to be $(-0.97) million. The composite uptick value of $8.3 million was eclipsed by the accrued downtick value of $9.27 million, thereby ensuring the up/down ratio of 0.9. For the week, the shares have posted returns of -0.15%.
Currently the company Insiders own 9.6% of Spark Therapeutics shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -7.14% . Institutional Investors own 70.62% of Spark Therapeutics shares. During last six month period, the net percent change held by insiders has seen a change of -1.85%. On the companys insider trading activities, Marrazzo Jeffrey D, director officer (Chief Executive Officer) of Spark Therapeutics, Inc., unloaded 600 shares at an average price of $60 on May 31, 2016. The total amount of the transaction was worth $36,000, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Spark Therapeutics (NASDAQ:ONCE) stock ended Monday session in the red zone in a volatile trading. The stock closed down 1.03 points or 1.92% at $52.55 with 720,748 shares getting traded. Post opening the session at $53, the shares hit an intraday low of $50.4 and an intraday high of $54.3348 and the price was in this range throughout the day. The company has a market cap of $1,440 million and the number of outstanding shares have been calculated to be 27,398,357 shares. The 52-week high of Spark Therapeutics (NASDAQ:ONCE) is $73.2 and the 52-week low is $21.2.
Many analysts have stated their opinion on the company shares. Jefferies initiates coverage on Spark Therapeutics (NASDAQ:ONCE) The brokerage firm has issued a Hold rating on the shares. The rating by the firm was issued on June 2, 2016.
Spark Therapeutics, Inc. (Spark) is engaged in developing products in the field of gene therapy. Sparks product candidate, SPK-RPE65, which is in Phase III clinical trial stage, targets a group of rare blinding conditions known as inherited retinal dystrophies (IRDs), caused by non-sex linked or autosomal recessive mutations in the RPE65 gene. Spark is also developing various follow-on product candidates targeting other IRDs, including SPK-CHM for the treatment of choroideremia (CHM). SPK-CHM is in Phase I/II dose-escalating clinical trial stage. The Companys product development portfolio includes product candidates targeting expression of genes in the liver, with a focus on hematologic disorders. The Company is also engaged in the development and commercialization of product candidates in its SPK-FIX program for the treatment of hemophilia B. Spark also has preclinical programs in development for the treatment of hemophilia A and neurodegenerative diseases.